P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 47 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H1 2016', provides in depth analysis on P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted pipeline therapeutics. 

The report provides comprehensive information on the P2X Purinoceptor 7 (P2Z Receptor or P2RX7), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for P2X Purinoceptor 7 (P2Z Receptor or P2RX7)
- The report reviews P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics and enlists all their major and minor projects 
- The report assesses P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for P2X Purinoceptor 7 (P2Z Receptor or P2RX7)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding P2X Purinoceptor 7 (P2Z Receptor or P2RX7) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) Overview 7
Therapeutics Development 8
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Products under Development by Stage of Development 8
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Products under Development by Therapy Area 9
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Products under Development by Indication 10
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Products under Development by Companies 14
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Therapeutics Assessment 16
Assessment by Monotherapy/Combination Products 16
Assessment by Mechanism of Action 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Companies Involved in Therapeutics Development 22
Affectis Pharmaceuticals AG 22
Axxam SpA 23
Biosceptre (Aust) Pty Ltd 24
Evotec AG 25
Johnson & Johnson 26
Medestea Research & Production S.p.A. 27
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Drug Profiles 28
AFC-5128 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
BIL-010t - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
BIL-011t - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
BIL-03n - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
BIL-03s - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
BIL-04s - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
BIL-06v - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
BIL-07v - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
EVT-401 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
JNJ-47965567 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
MED-1101 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Small Molecule to Antagonize P2X7 Receptor for Central Nervous System - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Small Molecules to Antagonize P2RX7 for CNS Disorders and Autoimmune Disorders - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Dormant Projects 41
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Discontinued Products 42
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Featured News & Press Releases 43
Dec 18, 2014: Alzheimer's Drug Discovery Foundation And Axxam Continue Their Successful Collaboration To Develop Novel Therapeutics For Alzheimer's Disease 43
Jul 22, 2014: Biosceptre Announces Positive Phase I Results for BIL-010t to Treat Basal Cell Carcinoma 43
Jan 25, 2012: Affectis Receives European Patent For AFC-5128 And Other P2X7 Antagonists 44
Jun 29, 2009: Evotec Announces The Successful Completion Of The First Phase I Study With EVT 401 44
Oct 09, 2008: Evotec Announces Phase I Initiation With P2X7 Antagonist 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 46
Disclaimer 47

List of Tables

Number of Products under Development for, H1 2016 8
Number of Products under Development by Therapy Area, H1 2016 9
Number of Products under Development by Indication, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 12
Comparative Analysis by Early Stage Products, H1 2016 13
Number of Products under Development by Companies, H1 2016 14
Products under Development by Companies, H1 2016 15
Assessment by Monotherapy/Combination Products, H1 2016 16
Number of Products by Stage and Mechanism of Action, H1 2016 17
Number of Products by Stage and Route of Administration, H1 2016 19
Number of Products by Stage and Molecule Type, H1 2016 21
Pipeline by Affectis Pharmaceuticals AG, H1 2016 22
Pipeline by Axxam SpA, H1 2016 23
Pipeline by Biosceptre (Aust) Pty Ltd, H1 2016 24
Pipeline by Evotec AG, H1 2016 25
Pipeline by Johnson & Johnson, H1 2016 26
Pipeline by Medestea Research & Production S.p.A., H1 2016 27
Dormant Projects, H1 2016 41
Discontinued Products, H1 2016 42